Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
NCT ID: NCT03339102
Last Updated: 2021-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
158 participants
OBSERVATIONAL
2018-01-25
2020-07-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis
NCT02916017
Surveillance of Humira Injection in Korean Patients
NCT01083121
A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
NCT01148225
Post-marketing Observational Study in Subjects With Rheumatoid Arthritis
NCT00234884
Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)
NCT01155570
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants who received Humira®
Non-infectious intermediate, posterior, or panuveitis patients who received Humira®
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients voluntarily signed a patient authorization \& informed consent form.
* Decision on the treatment with Humira® was made prior to any decision to approach the patient to participate in this study.
* Humira® treatment is indicated as per local Summary of Product Characteristics (SmPC) and professional and/or reimbursement guidelines.
Exclusion Criteria
* A patient who is participating on other interventional clinical trials
* Prior treatment with Humira®, including current course of Humira® started prior to baseline visit assessments.
19 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AbbVie Inc.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pusan National University Hosp /ID# 202026
Busan, Busan Gwang Yeogsi, South Korea
Soon Chun Hyang University Cheonan Hospital /ID# 204551
Cheonan, Chungcheongnam-do, South Korea
Yeungnam University Med Ctr /ID# 201361
Daegu, Daegu Gwang Yeogsi, South Korea
Seoul National Univ Bundang ho /ID# 201657
Seongnam, Gyeonggido, South Korea
Ajou University Hospital /ID# 201516
Suwon, Gyeonggido, South Korea
HanGil Eye Hospital /ID# 201655
Bupyeong, Incheon Gwang Yeogsi, South Korea
Wonkwang University Hospital /ID# 204545
Iksan, Jeonrabugdo, South Korea
Nune Eye Hospital /ID# 211613
Seoul, Seoul, South Korea
Gangnam Severance Hospital /ID# 202027
Seoul, Seoul Teugbyeolsi, South Korea
Samsung Medical Center /ID# 201515
Seoul, Seoul Teugbyeolsi, South Korea
Maryknoll Medical Center /ID# 201370
Busan, , South Korea
Chungbuk National Univ Hosp /ID# 204544
Cheongju-si, , South Korea
Apgujung St. Mary's Eye Center /ID# 210721
Gangnam-gu, , South Korea
Inje University Ilsan Paik Hos /ID# 204543
Goyang, , South Korea
Chosun University Hospital /ID# 204542
Gwangju, , South Korea
Seoul National University Hospital /ID# 201656
Seoul, , South Korea
Kim's Eye Hospital /ID# 205685
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
clinical study report synopsis
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P17-176
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.